Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimizing combination therapies with existing and future CML drugs.

PloS one - 23 Aug 2010

Katouli Allen A, Komarova Natalia L

Abstract excerpt

Small-molecule inhibitors imatinib, dasatinib and nilotinib have been developed to treat Chromic Myeloid Leukemia (CML). The existence of a triple-cross-resistant mutation, T315I, has been a challenging problem, which can be overcome by finding new inhibitors. Many new compounds active against T315I mutants are now at different stages of development. In this paper we develop an algorithm which can weigh different...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Multiple

Share to Drug Resistance, Neoplasm

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Probability

Share to Stochastic Processes

Source

Open in PubMed Open full text

Identifiers

PMID: 20808800
DOI: 10.1371/journal.pone.0012300
PMCID: PMC2925944

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Optimizing combination therapies with existing and future CML drugs.PMID 20808800Read ↗

Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemiaSemantic proximity Read ↗

Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Beyond IC50-A computational dynamic model of drug resistance in enzyme inhibition treatment.Semantic proximity Read ↗

Beyond IC <sub>50</sub> - A computational dynamic model of drug resistance in enzyme inhibition treatmentSemantic proximity Read ↗

Seeking Goldilocks During Evolution of Drug Resistance.Semantic proximity Read ↗

Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.Semantic proximity Read ↗

Development of an optimized dose for coformulation of zidovudine with drugs that select for the K65R mutation using a population pharmacokinetic and enzyme kinetic simulation model.Semantic proximity Read ↗

Application of different approaches to generate virtual patient populations for the Quantitative Systems Pharmacology model of erythropoiesisSemantic proximity Read ↗

An analysis of strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia with imatinib-resistant mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.